glp 1 agonist in heart failure JCI Early trials of GLP-1 based

BMJ 381 , e073312 (2023)

Key takeaways: GLP-1 is a rapid-acting gut hormone that regulates blood sugar and appetite by signaling insulin release and suppressing glucagon

And because the program is open to anyone, its flexible, scalable, and simple to integrate

This lack of standardization frustrates patients and providers alike

To help mitigate any side effects you might experience from these medications, your provider will likely have you start with a low dose of treatment and gradually increase it over time to reach the target dose

Atherosclerosis and GLP-1RA The clinical trials investigating the impact of GLP-1RA on cardiovascular health have shown that the incidence of MACE does not differ between the GLP-1R agonist and placebo groups until 1218 months after initiation of therapy, which aligns with the potential anti-atherogenic effect of GLP-1RA (Sattar et al